Morgan Stanley Verona Pharma PLC Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Verona Pharma PLC stock. As of the latest transaction made, Morgan Stanley holds 1,624,127 shares of VRNA stock, worth $135 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,624,127

Previous 1,483,753 9.46%

Holding current value

$135 Million

Previous $68.9 Million 49.65%

% of portfolio

0.01%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$44.81 - $69.63 $6.29 Million - $9.77 Million	140,374 Added 9.46%	1,624,127 $103 Million
Q4 2024 Feb 14, 2025	BUY	$28.71 - $47.02 $25.6 Million - $42 Million	892,844 Added 151.1%	1,483,753 $68.9 Million
Q3 2024 May 14, 2025	SELL	$15.46 - $30.16 $4.22 Million - $8.24 Million	-273,122 Reduced 31.61%	590,909 $17 Million
Q3 2024 Nov 14, 2024	SELL	$15.46 - $30.16 $4.22 Million - $8.24 Million	-273,122 Reduced 31.61%	590,909 $17 Million
Q2 2024 May 14, 2025	SELL	$11.48 - $17.02 $7.11 Million - $10.5 Million	-619,722 Reduced 41.77%	864,031 $12.5 Million
Q2 2024 Oct 17, 2024	BUY	$11.48 - $17.02 $6.09 Million - $9.04 Million	530,859 Added 159.33%	864,031 $12.5 Million
Q2 2024 Aug 14, 2024	BUY	$11.48 - $17.02 $6.09 Million - $9.04 Million	530,859 Added 159.33%	864,031 $12.5 Million
Q1 2024 Oct 17, 2024	SELL	$15.3 - $20.24 $8.12 Million - $10.7 Million	-530,859 Reduced 61.44%	333,172 $5.36 Million
Q1 2024 Aug 16, 2024	SELL	$15.3 - $20.24 $2.26 Million - $3 Million	-148,024 Reduced 30.76%	333,172 $5.36 Million
Q1 2024 May 15, 2024	SELL	$15.3 - $20.24 $2.26 Million - $3 Million	-148,024 Reduced 30.76%	333,172 $5.36 Million
Q4 2023 Aug 16, 2024	SELL	$11.94 - $20.47 $4.57 Million - $7.84 Million	-382,835 Reduced 44.31%	481,196 $9.57 Million
Q4 2023 Feb 13, 2024	BUY	$11.94 - $20.47 $4.86 Million - $8.33 Million	407,153 Added 549.89%	481,196 $9.57 Million
Q3 2023 Nov 15, 2023	SELL	$16.3 - $22.09 $112,225 - $152,089	-6,885 Reduced 8.51%	74,043 $1.21 Million
Q2 2023 Aug 14, 2023	SELL	$19.41 - $23.43 $2.43 Million - $2.93 Million	-124,968 Reduced 60.69%	80,928 $1.71 Million
Q1 2023 May 15, 2023	BUY	$18.06 - $25.27 $628,090 - $878,840	34,778 Added 20.32%	205,896 $4.13 Million
Q4 2022 Feb 14, 2023	BUY	$9.84 - $26.13 $1.63 Million - $4.34 Million	166,140 Added 3337.48%	171,118 $4.47 Million
Q3 2022 Nov 14, 2022	SELL	$4.14 - $13.59 $19,900 - $65,327	-4,807 Reduced 49.13%	4,978 $51,000
Q2 2022 Oct 27, 2022	BUY	$3.55 - $5.06 $1,178 - $1,679	332 Added 3.51%	9,785 $41,000
Q2 2022 Aug 15, 2022	BUY	$3.55 - $5.06 $1,178 - $1,679	332 Added 3.51%	9,785 $41,000
Q1 2022 Oct 27, 2022	SELL	$4.82 - $6.98 $1,600 - $2,317	-332 Reduced 3.39%	9,453 $47,000
Q1 2022 May 13, 2022	BUY	$4.82 - $6.98 $10,531 - $15,251	2,185 Added 30.06%	9,453 $47,000
Q4 2021 Feb 14, 2022	SELL	$3.91 - $7.08 $3,620 - $6,556	-926 Reduced 11.3%	7,268 $48,000
Q3 2021 Nov 15, 2021	BUY	$5.29 - $6.35 $43,346 - $52,031	8,194 New	8,194 $45,000

Others Institutions Holding VRNA

# of Institutions

291

Shares Held

74.3M

Call Options Held

933K

Put Options Held

1.98M

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $5.08B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account